No study has comprehensively examined the effects of these SNPs on natural history of HCV cirrhosis. We tested the association between clinical, demographic, and genetic data and outcomes in patients with HCV cirrhosis. Methods: We performed a retrospective cohort study of 169 subjects with HCV and biopsyproven cirrhosis who did not have evidence of decompensation or HCC at the time of biopsy. Genotyping was performed on formalin fixed paraffin embedded liver tissue specimens. Cox proportional hazards model was used to determine the hazard ratio for risk of AZD6738 price decompensation (ascites, encephalopathy, variceal bleed, HCC, liver death). Results: During

a median follow up of 6.6 years, 66 patients experienced a decompensation event. EGF AA, PNPLA3 CC and IL28B CC were each associated with a decreased decompensation

risk in univariate analysis. In multivariable Cox regression modeling, EGF AA genotype was associated with a significantly decreased risk of decompensation (HR = 0.34, p=0.03) even after adjusting for other univariate significant predictors (Table). Conclusions: HCV cirrhotics with the EGF AA genotype, a functional polymorphism associated with decreased EGF production, have a decreased risk of clinical outcomes. These data imply that EGF genotyping will have utility in identifying persons at risk for disease progression. Further study of the predictive value

of EGF genotyping in patients with earlier stages and other etiologies of liver disease is warranted. Disclosures: ABC294640 concentration Kenneth Tanabe – Patent Held/Filed: Massachusetts General Hospital Raymond T. Chung – Advisory Committees or Review Panels: Idenix; Consulting: Enanta; Grant/Research Support: Gilead, Merck, Mass Biologic, Gilead The following people have nothing to disclose: Lindsay Y. King, Kara B. Johnson, Hui Zheng, Lan Wei, Thomas Gudewicz, Ajayi Tokunbo, Nneka Ufere, Bryan C. Fuchs Background and Aims: Highly effective antiviral therapy will lead to increased number of patients with successful eradication of hepatitis C (HCV). While the overall incidence Tacrolimus (FK506) of hepatocellular carcinoma (HCC) is expected to decrease, the number of HCC development after HCV eradication may paradoxically increase. The aim of the present study was to estimate risk factors for development of HCC following successful eradication of HCV. Methods: Multicenter study was conducted by Japanese Red Cross Liver Study Group, involving 18 hospitals and medical centers nationwide. A total of 785 genotype 1b chronic hepatitis C patients who had successful eradication of HCV by interferon therapy from 1992 to 2009 were enrolled. Median period of follow up was 6.5 years.